Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging

Cancer Research

Volumn 74, Issue 3, 2014, Pages 896-907

  Allen, Michael D ^a   Luong, Phuong ^a   Hudson, Chantelle ^a   Leyton, Julius ^a   Delage, Barbara ^a   Ghazaly, Essam ^a   Cutts, Rosalind ^a   Yuan, Ming ^a   Syed, Nelofer ^b   Lo Nigro, Cristiana ⁱ   Lattanzio, Laura ⁱ   Chmielewska Kassassir, Malgorzata ^j   Tomlinson, Ian ^d   Roylance, Rebecca ^a,c   Whitaker, Hayley C ^e   Warren, Anne Y ^e   Neal, David ^e   Frezza, Christian ^f   Beltran, Luis ^c   Jones, Louise J ^a,c   Chelala, Claude ^a   Wu, Bor Wen ^k   Bomalaski, John S ^k   Jackson, Robert C ^g   Lu, Yong Jie ^a   Crook, Tim ^h   Lemoine, Nicholas R ^a   Mather, Stephen ^a   Foster, Julie ^a   Sosabowski, Jane ^a   Avril, Norbert ^a   Li, Chien Feng ^l,m,n   Szlosarek, Peter W ^a,c   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Pharmacometrics Ltd   (United Kingdom)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j MEDICAL UNIVERSITY OF LODZ   (Poland)

^k Polaris Group   (United States)

^l CHI MEI MEDICAL CENTER   (Taiwan)

^m SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

ⁿ NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARGININOSUCCINATE SYNTHASE; DIHYDROFOLATE REDUCTASE; FLUORODEOXYGLUCOSE F 18; PEMETREXED; THYMIDINE; THYMIDYLATE SYNTHASE;

ARTICLE; ASIAN; BLADDER CANCER; CAUCASIAN; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EPIGENETICS; GENETICS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ARGININOSUCCINATE SYNTHASE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA METHYLATION; DRUG SYNERGISM; FEMALE; GLUTAMATES; GUANINE; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASM INVASIVENESS; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PYRIMIDINES; URINARY BLADDER NEOPLASMS; X-RAY MICROTOMOGRAPHY;

EID: 84893856177     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1702     Document Type: Article

References (51)

1. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64.
2. Sonpavde G, Watson D, Tourtellott M, Cowey CL, Hellerstedt B, Hutson TE, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer 2012;10:1-5.
3. Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 2009;28:355-67.
4. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62: 5443-50.
5. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31.
6. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009; 69:700-8.
7. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010;126:2762-72.
8. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887-99.
9. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/ HIF-1alpha/Sp4. Mol Cancer Ther 2009;8:3223-33.
10. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009;125:1454-63.
11. Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 2010;9:535-44.
12. HuangHY,WuWR, WangYH,WangJW, Fang FM, Tsai JW, et al.ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res 2013;19:2861-72.
13. Old LJ, Boyse EA, Campbell HA, Daria GM. Leukaemia-inhibiting properties and L-asparaginase activity of sera from certain South American rodents. Nature 1963;198:801.
14. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005; 23:7660-8.
15. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28: 2220-6.
16. Szlosarek PW, Luong P, Phillips MM, Baccarini M, Ellis S, Szyszko T, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 2013;31:e111-3.
17. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH 3rd, Gonzalez-Zulueta M, et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993;53:4066-70.
18. Linnenbach AJ, Robbins SL, Seng BA, Tomaszewski JE, Pressler LB, Malkowicz SB. Urothelial carcinogenesis. Nature 1994;367:419-20.
19. Veerakumarasivam A, Goldstein LD, Saeb-Parsy K, Scott HE, Warren A, Thorne NP, et al. AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. Cell Cycle 2008;7:3525-33.
20. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986;46:5419-25.
21. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
22. Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 2012;3:e342.
23. Brockenbrough JS, Souquet T, Morihara JK, Stern JE, Hawes SE, Rasey JS, et al. Tumor 30-deoxy-30-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors. J Nucl Med 2011;52:1181-8.
24. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007;25:265-70.
25. Li Y, Li X, Dai H, Sun X, Li J, Yang F, et al. Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer. BJU Int 2009;103:547-52.
26. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-601.
27. Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010;28:1534-9.
28. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-8.
29. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000;6:488-92.
30. Osunkoya BO, Adler WH, Smith RT. Effect of arginine deficiency on synthesis of DNA and immunoglobulin receptor of Burkitt lymphoma cells. Nature 1970;227:398-9.
31. Yamauchi K, Komatsu T, Kulkarni AD, Ohmori Y, Minami H, Ushiyama Y, et al. Glutamine and arginine affect Caco-2 cell proliferation by promotion of nucleotide synthesis. Nutrition 2002;18:329-33.
32. Rhoads JM, Chen W, Gookin J, Wu GY, Fu Q, Blikslager AT, et al. Arginine stimulates intestinal cell migration through a focal adhesion kinase dependent mechanism. Gut 2004;53:514-22.
33. Rhoads JM, Liu Y, Niu X, Surendran S,WuG. Arginine stimulates cdx2-transformed intestinal epithelial cellmigration via a mechanism requiring both nitric oxide and phosphorylation of p70 S6 kinase. J Nutr 2008;138:1652-7.
34. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998;273: 14484-94.
35. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010;176: 3062-72.
36. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
37. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 2010;10:405-12.
38. Brasse-Lagnel CG, Lavoinne AM, Husson AS. Amino acid regulation of mammalian gene expression in the intestine. Biochimie 2010;92: 729-35.
39. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84.
40. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007;67:309-17.
41. Stelter L, Fuchs S, Jungbluth AA, Ritter G, Longo VA, Zanzonico P, et al. Evaluation of arginine deiminase treatment in melanoma xenografts using F-FLT PET. Mol Imaging Biol 2013;15:768-75.
42. Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, et al. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med 2012;53:281-6.
43. Morrow K, Hernandez CP, Raber P, Del Valle L, Wilk AM, Majumdar S, et al. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia 2013;27:569-77.
44. Dabrowska-Mas E, Fraczyk T, Ruman T, Radziszewska K, Wilk P, Ciesla J, et al. Tyrosine nitration affects thymidylate synthase properties. Org Biomol Chem 2012;10:323-31.
45. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, et al. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004;43: 614-22.
46. Kokkinakis DM, Liu X, Chada S, Ahmed MM, Shareef MM, Singha UK, et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 2004;64:7513-25.
47. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148: 259-72.
48. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al.Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012;336:1040-4.
49. Possemato R, Marks KM, Shaul YD, Pacold ME, KimD, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011;476:346-50.
50. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61:8256-62.
51. Szlosarek PW, Steele JP, Sheaff MT, Avril NE, Szyszko T, Ellis S, et al. A randomised phase II trial of pegylated arginine deiminase (ADI-PEG20) in patients with malignant pleural mesothelioma (MPM). In: 2013 World Conference on Lung Cancer; 2013 Oct 27-30; Sydney. Abstr no. MO09.02.